More companies than ever before are realizing the potential of gene therapies to treat a wide range of ophthalmic disorders but in practice there are still hurdles to overcome.
A variety of unique challenges must be addressed to effectively bring gene therapies to patients, from developing preclinical models that accurately translate to the clinic to validating clinical endpoints that will satisfy regulators.
Gene Therapy for Ophthalmic Disorders will unite industry leaders across the ophthalmology space to overcome the specific delivery and drug development challenges faced by companies developing gene therapies for ophthalmic diseases.
Don’t get left behind. Join pioneering companies including Novartis, Gensight Biologics and Spark Therapeutics to revolutionize the treatment of ophthalmic diseases.
Conference Only Standard Rate: USD 2899.0,
Conference + 1 Workshop Standard Rate: USD 3498.0,
Conference + 2 Workshops Standard Rate: USD 4097.0
Speakers: Wiley Chambers, FDA, Thierry Bordet, Eyevensys, Dan Chung, Spark Therapeutics, Viral Kansara, Clearside Biomedical Inc., Brian Mansfield, Foundation for Fighting Blindness, Adam Rogers, Hemera Biosciences, Magali Taiel, Gensight Biologics, Abraham Scaria, IVERIC bio, Samantha Vieira, Biogen, Ashley Winslow, Odylia Therapeutics, Claire Gelfman, Adverum